Presagen AI Open Projects for clinics enables scalable unbiased AI medical products to be co-created from globally diverse datasets

Presagen has launched a new AI product for clinics at the HLTH conference in Las Vegas, aimed at revolutionizing the way AI is applied to healthcare.... more

Tuesday, October 29th, 2019 - Presagen

Plexoval Exosome Wound Healing Human Study Starts

An important step forward for Exopharm: A clinical-stage company and world leader in exosome therapeutics for regenerative medicine.... more

Monday, August 26th, 2019 - Exopharm

Clinical stage Exopharm announces a successful Placement and the opening of a Share Purchase Plan

Melbourne, Australia: Exopharm Limited (ASX:EX1) has finalised a A$4.44 million share placement to new institutional and sophisticated investors.  A further Share Purchase Plan (SPP) to existing shareholders has a target raise of A$2.7m.... more

Friday, July 26th, 2019 - Exopharm

Exopharm Secures Ethics Approval for the Plexoval Clinical Trial

Melbourne, Australia: Exopharm Limited (ASX:EX1) has received approval from Melbourne Health Human Research Ethics Committee to commence the PLEXOVAL wound healing study with its PlexarisTM product under the Australian Clinical Trials Notification (C... more

Monday, July 22nd, 2019 - Exopharm

The Next Big Thing in Regenerative Medicine: Exosomes

Stem cell therapy once seemed beguilingly simple. It was thought that by injecting additional stem cells into the body, the new cells would transform the way that we treat certain conditions. But nearly 20 years on, the general safety and efficacy of... more

Thursday, July 18th, 2019 - Exopharm

If you have concerns about skin cancer you must read this

Most skin cancers are a locally destructive cancerous growth of the skin. They originate from the cells of the outer layers of the skin (the epidermis) and unlike malignant melanoma, the vast majority of these sorts of skin cancers rarely s... more

Monday, July 15th, 2019 - Global Health Direct Pty Ltd

AI medical imaging company Presagen raises $4.5 million seed funding to globally commercialize its flagship Life Whisperer fertility product

AI medical imaging company Presagen has raised AUD$4.5 million Seed investment from Australian and U.S. private investors, and the South Australian Government. The investment will accelerate the commercialization of Presagen’s Life Whisperer pr... more

Friday, April 26th, 2019 - Life Whisperer Diagnostics Pty Ltd

Australian Research leads to global solution for treatment of Actinic Keratosis (AK Sunspots)

Actinic Keratosis (AK) is that scaly, red, and occasionally itchy patch of skin, resembling a mole, that usually appears on patients over 50 years old, but can manifest in younger adults particularly with prolonged sun exposure. The percentage risk o... more

Tuesday, April 9th, 2019 - Global Health Direct Pty Ltd

World breakthrough in treatment of sunspots launched first in Australia for the 2019 summer

After five years of clinical research, a topical treatment for sunspots (Actinic Keratosis) that was developed using Australian technology, is now being released in Australia and the USA.... more

Monday, January 21st, 2019 - Global Health Direct Pty Ltd

Life Whisperer and Presagen co-founder Jonathan Hall awarded MIT Technology Review Innovator Under 35 Asia Pacific

Life Whisperer and Presagen co-founder Dr Jonathan Hall has been awarded the prestigious MIT Technology Review Innovator under 35 Asia Pacific title for his work in the application of AI for medical imaging, and in particular embryo assessment t... more

Thursday, November 22nd, 2018 - Life Whisperer Diagnostics Pty Ltd